Abstract Young Black women in the United States are disproportionately afflicted with breast cancer, a proportion of which may be due to BRCA1 and BRCA2 (BRCA) gene mutations. In a cancer registry-based sample of young Black women with breast cancer, we evaluated: (1) the prevalence of BRCA mutations detected through full gene sequencing and large rearrangements testing and (2) proportions that accessed genetic services pre-dating study enrollment. Black women diagnosed with invasive breast cancer ≤age 50 years in 2009-2012 were recruited through the Florida Cancer Registry. Participants completed genetic counseling, a study questionnaire, and consent for medical record release. Saliva specimens were collected for BRCA testing. Overall, 13 participants (9 %) had BRCA mutations detected (including 11 through full gene sequencing and two through large rearrangements testing). One of these large rearrangements, BRCA1 (delExon8), was identified in a participant who had previously tested negative on clinical comprehensive BRCAnalysis that was performed prior to undergoing a lumpectomy. Although all 144 participants met national criteria for referral for cancer genetic risk assessment, 61 (42 %) were referred for genetic counseling and/or had genetic testing preceding study enrollment, and only 20 (14 %) received genetic counseling. Our findings emphasize the importance of large rearrangements testing to increase detection of deleterious BRCA mutations in young Black women with breast cancer. The registry-based design of our study increase the generalizability of findings compared with efforts focused on clinic-based populations. Furthermore, results suggest efforts are needed to improve access to genetic counseling and testing.
Introduction
Young Black women bear a disproportionate burden associated with breast cancer incidence and mortality compared with their White counterparts (American Cancer Society 2011). Given that early onset breast cancer is a hallmark feature of germline mutations in the inherited breast cancer susceptibility genes, BRCA1 and BRCA2 (BRCA ), a portion of these breast cancers may be attributed to mutations in these genes. Identifying BRCA mutations can profoundly influence health outcomes. Mutations in the BRCA genes confer a lifetime risk of breast cancer in the range of 60-70 % (Antoniou et al. 2003; Chen and Parmigiani 2007; Litton et al. 2011) , as well as a much higher risk of a second primary breast cancer than non-carriers, particularly for those diagnosed at a younger age (Graeser et al. 2009; Malone et al. 2010) . Those identified with mutations may avail themselves to the latest cancer risk management strategies including increased surveillance and preventive surgeries to improve their outcomes (Narod and Offit 2005) .
Studies conducted in primarily White populations indicate that an estimated 5 % of all breast cancers are due to mutations in the BRCA genes (Malone et al. 2006) . However, the prevalence estimates in Black women remain uncertain, mostly due to their reported low uptake of BRCA testing and bias inherent in clinic-based samples (Newman 2005) . Additionally, minority-serving physicians have been found to be less likely to have ever ordered a genetic test for breast cancer or to have referred a patient for genetic testing compared with those serving a smaller proportion of minorities (Shields et al. 2008) . Despite these concerns about disparities, the overall proportion of young Black women with breast cancer who access genetic counseling and BRCA testing remains uncertain due to under-representation of Black women in the only population-based study of young women with breast cancer we are aware of that reported on access to genetic services (Anderson et al. 2012) .
The majority of BRCA gene mutations are detected through full gene sequencing; however, an additional 10 % of all mutations are estimated to be large rearrangements, which cannot be detected through sequencing. Detection of a large rearrangement requires additional testing through different technologies such as multiplex ligation-dependent probe amplification (MLPA) (Kang et al. 2010; Palma et al. 2008; Roa et al. 2011) . Until recently within the United States, clinical testing for BRCA mutations was mainly available through Myriad Genetics (Myriad), the company that used to own the patent on these genes (Myriad Genetics Laboratories and Pharmaceuticals). However, this is no longer the case since the ruling in June 2013 by the U.S. Supreme Court that genes are not patentable because they are products of nature. Prior to the beginning of 2013, when clinical BRCA testing was ordered through Myriad, the standard test was called "Comprehensive BRACAnalysis," which included BRCA sequencing and testing for five rearrangements in BRCA1 (which was added in 2003) (Shannon et al. 2011) . However, this test is estimated to miss up to 10 % of all mutations (Kang et al. 2010; Palma et al. 2008; Roa et al. 2011) . Testing for additional large rearrangements has been available through Myriad since 2006 (referred to as "BRACAnalysis Rearrangement Testing" or "BART"), yet it had to be ordered separately. Rearrangement testing has very recently become automatically included as part of Myriad's new standard test that is referred to as "integrated BRACAnalysis." However, rearrangement testing continues to be billed to insurers as a separate cost of $700, and this cost is not yet covered by all insurers even when women meet insurers' criteria for BRCA testing. Furthermore, the longstanding uncoupling of BART testing from comprehensive BRACAnalysis has resulted in an out-of-pocket expense, even among many of those who had health insurance coverage for BRCA testing at the time they were tested. Fortunately for some patients, the cost of BART has and continues to be covered through Myriad when a patient lacks coverage for it through their health insurance, and the lab is provided with information from the healthcare provider that the patient is at ≥30 % risk of having a BRCA mutation or the patient meets internal laboratory criteria (NCCN Guidelines Updated to Include BRACAnalysis® Large Rearrangement Test (BART ™)). Despite the option for some patients to receive free BART testing, there have been challenges at the provider level to identify those who qualified for this option, as demonstrated in our Florida-wide survey of providers who order BRCA testing (Pal et al. 2013b) .
Based on published data through Myriad Genetics, the frequency of mutations detected through large rearrangements testing may differ by ethnic background (Judkins et al. 2012) . However, there have been very limited studies of BRCA mutations among population-based samples of young Black women with breast cancer, and none of these have included large rearrangements testing (Pal et al. 2013a; John et al. 2007; Malone et al. 2006; Newman et al. 1998) . Through a population-based sample of Black women with early onset breast cancer recruited through the Florida state cancer registry, the objective of the current study was to assess: (1) the prevalence of BRCA mutations detected through full gene sequencing and large rearrangement testing and (2) proportion of women who accessed genetic services pre-dating study enrollment.
Materials and methods
Eligible patients were self-identified Black women diagnosed with invasive breast cancer at or below age 50 years between the years 2009 and 2012 who were living in Florida at the time of diagnosis and alive at time of contact. Upon approval of the institutional review boards of the University of South Florida and the Florida Department of Health (DOH), registry-based recruitment was initiated. The Florida State Cancer Registry released patient contact information and available clinical (i.e., age at diagnosis, stage of diagnosis, histologic subtype) and demographic (i.e., county of residence, marital status, primary payor at diagnosis) information on all 913 eligible participants that together constitute the population of interest.
Participants were recruited using previously described state-mandated recruitment methods (Pal et al. 2010) . A sample of 481 eligible women were sucessfully contacted and asked to: (1) provide verbal and written informed consent, including medical records release; (2) complete a study questionnaire, which included sociodemographic, epidemiologic, and lifestyle factors as well as information about referral for genetic counseling and/or testing predating study enrollment; (3) receive telephone genetic counseling to discuss inherited breast cancer with a certified genetic counselor, during which a three-generation pedigree was generated (for participants who reported prior clinical BRCA testing, results were obtained through signed medical releases and used during the pre-test genetic counseling session); and (4) provide a mailed saliva sample for DNA testing.
BRCA testing was performed on participants through DNA extracted from the saliva specimen. Testing included full gene sequencing and comprehensive rearrangement testing through MLPA of the BRCA1 and BRCA2 genes, as previously described (Zhang et al. 2011) . Demographic and clinical characteristics of all young Black women eligible to participate, as well as the subset of 144 participants for whom genetic testing was completed, were summarized using descriptive statistics, including means, standard deviations, and frequencies. Comparisons were made using large sample z-tests and chisquare goodness-of-fit tests to assess whether this subset differed from the overall population for demographic and clinical characteristics available from the cancer registry. All statistical tests were two-sided and considered statistically significant at a level of p ≤0.05. Mutation prevalence and proportions of those who accessed genetic counseling and/or testing services were calculated along with 95 % confidence intervals.
Results
Demographic and clinical information on the 144 participants who completed genetic counseling and testing are similar to demographic and clinical characteristics of all 913 individuals that comprise the entire population, as shown in Table 1 . The majority of participants had private insurance. Mean age of participants at breast cancer diagnosis was 43 years, with approximately half with stage 1 disease. Approximately 43 % of participants were married (including common law), and over one third had an annual household income below $50,000.
The number of family members with breast and/or ovarian cancers are compared in Table 2 according to whether participants received genetic testing prior to the study and also according to BRCA carrier status. A total of 13 mutations in the BRCA genes were detected in the 144 participants (i.e., 9.0 %; 95 % Confidence Interval (CI) 4.9 % to 14.9 %), including 11 detected through gene sequencing and two detected through large rearrangement testing (Table 3) . Of the women in whom we identified mutations, six had previously undergone clinical BRCA testing prior to study enrollment, and all but one of these women had a mutation detected on clinical testing. In this patient, who had undergone prior comprehensive BRACAnalysis, a BRCA1 mutation (BRCA1 del exon 8) was identified in our study through large rearrangements testing. Review of this participant's medical records indicated that she was 34 years at diagnosis and had testing performed in the pre-surgical setting, prior to definitive surgical treatment. Following receipt of her clinical genetic test result, she had a lumpectomy as part of her breast cancer treatment. Review of her family history indicated multiple first-, third-, and fourth-degree relatives with breast cancer (as illustrated in Fig. 1 ). Based on the Myriad risk assessment model, she had an a priori risk of 21.2 % for having a BRCA mutation. The other mutation detected through large rearrangements testing (BRCA1 ins exon 13) is one of the five BRCA1 rearrangements included as part of comprehensive BRACAnalysis, in a woman who was 45 years at diagnosis who had not received prior genetic testing.
Among the 144 participants, all met current National Comprehensive Cancer Network (NCCN) guidelines for referral for cancer risk assessment (Genetic/Familial High-risk Assessment: Breast and Ovarian 2012). Slightly less than half (n =61; 42 %; 95 % CI 34 %-51 %) were referred by a healthcare provider for genetic counseling and/or underwent genetic testing prior to study enrollment. However, of the subset of 43 women who were referred for genetic counseling, only 20 (14 % of all participants; 95 % CI 9 %-21 %) reported meeting with a genetic counselor to learn about their risk for breast or ovarian cancer (as illustrated in Fig. 2 ). Based on our review of prior BRCA test results from the commercial laboratory following signed release by the participants, we determined that 16 (11 %) had both counseling and testing, four (3 %) had genetic counseling but no testing, and 25 (17 %) had BRCA testing but no genetic counseling. An additional four participants reported having had genetic testing; however, the commercial laboratory had no record indicating they were tested. In total, 41 (28 %; 95 % CI 21 %-37 %) participants were tested through comprehensive BRACAnalysis prior to our study, of whom 12 also received BART testing.
Discussion
Our efforts, to the best of our knowledge, are the first to focus on a population-based sample of young Black women with breast cancer, in which the main objective was investigation of BRCA mutation prevalence through both sequencing and large rearrangement testing of both BRCA1 and BRCA2. In contrast, two of three prior studies in which BRCA testing was conducted in population-based samples with relatively large numbers of Black women included BRCA1 but not BRCA2 sequencing (John et al. 2007; Newman et al. 1998) . This is particularly problematic because in the third population-based study, Malone et al. (2006) reported that BRCA1 mutations were significantly less common among their 483 Black cases (1.4 %) compared with 1,145 White cases (2.4 %), and BRCA2 mutations were slightly more common among Black cases (2.6 % versus 2.1 %). Two thirds of the cases in the study by Malone et al. (2006) were age 45 years and above at diagnosis, and large rearrangement testing was not performed. Our study is unique because we only included Black women age 50 years and below, and we also tested all participants for large rearrangements. Due to these differences between the studies, it is not surprising that our overall prevalence of BRCA mutations was more than twice as high as the Malone et al. 2010 study (9 % compared with 4 %). Our findings, along with findings of prior studies, indicate similar prevalence estimates of BRCA mutations in Blacks and Whites (Haffty et al. 2009; Hall et al. 2009; Malone et al. 2006) , despite the higher prevalence of triple negative breast cancers (Carey et al. 2006; Lund et al. 2008) , disproportionate numbers with early onset disease (American Cancer Society 2011; , and higher mortality rates (American Cancer Society 2011; 2009) in Black women.
Data on the prevalence of BRCA large rearrangements in different ethnic groups, including African Americans, have been published through Myriad Genetics. In this report, patients were subdivided into a "high-risk" group (which was comprised of patients who met specific eligibility criteria developed by the testing laboratory which qualified them to have additional large rearrangements testing at no charge) as well as an "elective" group (which comprised individuals who pursued additional large rearrangements testing but did not meet testing laboratory eligibility criteria for free testing) (Judkins et al. 2012) . In African American women within the high-risk group, mutations were detected through comprehensive BRACAnalysis (which includes full gene sequencing and testing for five BRCA1 large rearrangements) and large rearrangements testing (called "BART" by the testing laboratory) in 26.9 % and 2.4 % of all samples tested, respectively. This can be contrasted with the elective group, in which mutations were detected in 11.4 % and 0.1 %, respectively. Thus, large rearrangements accounted for a small proportion of overall mutations detected in the Myriad study. In contrast, a clinic-based study identified large rearrangements, which would not have been detected with BRACAnalysis, in seven of 136 (5 %) non-Ashkenazi Jewish individuals, and these seven mutations constituted (16 %) of the 44 total mutations detected (Palma et al. 2008 ). In our study, the overall proportion of participants with a large rearrangement was small. Nevertheless, one out of 13 (7.6 %) mutations we identified would not have been detected through Comprehensive BRACAnalysis. Interestingly, this large rearrangement is one of three that together made up 60.5 % of all large rearrangements detected in African Americans in the Myriad dataset (Judkins et al. 2012) . Finally, another chart review study reported on 257 patients in whom BART tests were performed at a single institution over a 3-year period. Results indicated that 40 % of patients in whom mutations were detected through BART did not meet the laboratory criteria for free testing (Shannon et al. 2011 ). Based on these results, the authors concluded that BART testing should be included when Comprehensive BRACAnalysis is offered. Our study also supports this conclusion in that the participant in whom the BRCA1 del exon 8 mutation was detected had previously undergone comprehensive BRACAnalysis (with negative results) and did not meet eligibility criteria for free BART testing based on the Myriad risk assessment model. Despite its limitations, the Myriad model is a commonly used method in the U.S. of estimating the chances that a BRCA (43) 17 (42) 44 (43) 1 4 (31) 35 (27) 5 (12) 34 (33) 2 2 (15) 24 (18) 11 (27) 15 (15) 3 0 (0) 11 (8) 3 (7) 8 (8) ≥4 2 (15) 5 (4) 5 (13) 2 (2) Myriad risk assessment 0-5 % 9 (69) 90 (69) 28 (68) 71 (69) 6-15 % 2 (15.5) 30 (23) 6 (15) 26 (25) ≥16 2 (15.5) 11 (8) 7 (17) 6 (6) d Participant was diagnosed with bilateral breast cancer and also had blood drawn for BRCA testing but never tested because insurance did not cover e Participant was diagnosed with another primary breast cancer diagnosis at age 28 years, prior to enrollment mutation will be identified. Nevertheless, our participant's family history is very striking, and assessment with the Manchester scoring system (which is less commonly used in the U.S., but has been demonstrated to be more accurate than the Myriad risk model in a U.K. study) would have given her a >50 % chance of a BRCA mutation (Evans et al. 2004 (Evans et al. , 2005 . Ultimately, our results and those from prior studies suggest that the uncoupling of Comprehensive BRACAnalysis and BART has lead to incomplete BRCA testing in patients. This has been formally recognized in the 2012 NCCN practice guidelines (Genetic/Familial High-risk Assessment: Breast and Ovarian 2012), which were updated to recommend that large rearrangements testing should be considered part of standard BRCA testing for any patient in whom testing is indicated. Our study highlights the importance of these guidelines. Additionally, the recent ability for other labs to offer BRCA testing in the U.S. and recent changes by Myriad so that sequencing and large rearrangement testing are automatically ordered together are important steps to increase access to Fig. 2 Venn diagram showing the number of participants referred for genetic counseling (+refer), number who attended genetic counseling (+attend), and number who received BRCA testing (+test) prior to study enrollment. The minus sign indicates the absence of a referral, attendance, or testing Fig. 1 Pedigree of participant with no prior mutation on BRACAnalysis who has a large gene rearrangement testing and help ensure that testing is complete. Additionally, more insurers are covering the cost of large rearrangement testing. Specifically, Medicare guidelines were revised as of 01 October 2012, to include large rearrangements testing in any patient who qualified for comprehensive BRACAnalysis, and other insurers such as Tricare and United Health have followed suit. Thus, at a policy level, insurance coverage for this testing continues to expand, yet this fails to address large rearrangements testing for patients who have previously had Comprehensive BRACAnalysis. Furthermore, the historic lack of insurance coverage for large rearrangements testing and prior requirement to order these tests separately means that some women with hereditary breast and ovarian cancer who were previously tested (and their affected family members) remain unidentified. Although no standard clinical guidelines exist for these patients, follow-up mechanisms through treating healthcare providers to re-contact them about the updated testing recommendation by NCCN may be appropriate, when feasible (Rubinstein 2008) .
Our findings regarding referral and clinical access to genetic counseling and/or testing demonstrate an opportunity to enhance adherence to NCCN guidelines for referral for cancer risk assessment services. All 144 of our study participants met NCCN referral guidelines based on their personal history of breast cancer at or below age 50 years. Of these, only 45 (31 %) had genetic counseling and/or testing, although an additional 16 (11 %) were referred but did not follow through with genetic counseling or testing (as illustrated in Fig. 2) . These findings provide a population-based estimate of young Black women with breast cancer who are referred to and access genetic services and also highlight the need to improve awareness about identifying appropriate patients for BRCA risk assessment at the provider level. A recently published study of 125 Black women at high risk for BRCA mutations found that physicians had recommended genetic counseling in over two thirds of the sample, but the likelihood of recommendation was significantly lower among participants who were recruited through the community (Thompson et al. 2012) . Prior population-based efforts using a state cancer registry to determine patient referral and access to genetic services in young women with breast cancer is limited to a single survey of women with breast cancer diagnosed below age 50 years throughout the state of Michigan. Of all 289 respondents, 42.2 % reported receiving genetic counseling. Blacks represented only 8.3 % of respondents, yet comprised 21.3 % of non-respondents (Anderson et al. 2012) . Nevertheless, among the 24 Black participants, only five (21 %) reported having received genetic counseling, which is higher than the proportion who reported having received genetic counseling in our study (i.e., 14 %). The difference in these rates may simply be due to sampling error given the small number of Black participants in the Michigan study. However, it is also possible that the Michigan results reflect rates higher than national averages due to the policy work conducted through Michigan DOH to enhance access to BRCA-related counseling and testing . Our results are also subject to state-specific factors. In particular, the low numbers of genetic professionals in Florida (Pal et al. 2013b ) coupled with Myriad Genetics' direct-toconsumer marketing campaigns in Florida (Matloff and Caplan 2008) Robson et al. 2010) . The lack of adherence to existing national guidelines for performing genetic counseling prior to clinical BRCA testing suggests there remain tremendous opportunities for education and outreach at the provider level.
There were several strengths in our study, including our registry-based design, which enabled recruitment of a population-based sample that was not significantly different than the entire population of interest in terms of several key clinical and demographic variables available through the State Cancer Registry. This suggests that our participants are likely to be a representative sample of our population of interest and thereby enhances the generalizability of our findings. Nevertheless, other unmeasured differences between our sample and the population of interest could exist and the possibility of bias cannot be eliminated entirely. Furthermore, our sample size limits our ability to draw firm conclusions about the prevalence of BRCA mutations in unselected young Black women with breast cancer. However, our 95 % confidence interval indicates the mutation prevalence among this understudied population probably falls between 5.4 % and 14.8 %. Interestingly, the mutation prevalence among the group of women who were tested prior to the study was higher than among the women who were not previously tested. This could simply be due to chance, as we are underpowered to detect statistically significant differences between these subgroups. However, we believe that another possible explanation for the differences could be that individuals at higher risk to have a mutation are more likely to have been tested. Table 2 suggests a potential trend for more women with very strong family histories of cancer (i.e., women in the highest Myriad risk classification and women with four or more close relatives with breast and/or ovarian cancer) to have received testing prior to the study. Nevertheless, caution is necessary when drawing any conclusions given the small number of women who fall into these categories.
An added strength is that we collected information on pretest counseling and clinical BRCA testing prior to study enrollment, which has not been done in other population-based studies that have reported on BRCA prevalence (John et al. 2007; Malone et al. 2006; Newman et al. 1998 ). This allowed us to estimate a population-based prevalence of pretest counseling and BRCA testing among young Black women, thereby adding to the limited literature available on this topic (Anderson et al. 2012) . In both our study and the Michigan study, receipt of genetic counseling was self-reported and subject to bias. We also do not know what type of health care providers counseled the participants. Nevertheless, taken together, results from these two studies suggest the presence of a gap in access to genetic counseling among Black women. Finally, unlike the Michigan study, we took a more comprehensive approach to data collection, which resulted in our ability to also report on the prevalence of BRCA testing, and this estimate is less subject to recall bias because we obtained copies of prior BRCA test results to verify self-reported genetic testing.
In summary, results from our study suggest that large rearrangements testing in young Black women with breast cancer increases the yield of BRCA testing and reiterates the importance of offering this to all high-risk patients in whom comprehensive BRACAnalysis was performed. Furthermore, there remain additional opportunities to increase awareness about cancer risk assessment services among providers to promote adherence to existing best practices guidelines.
